Patents by Inventor Carine Paturel

Carine Paturel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT WITH ANTI-KIR3DL2 AGENTS
    Publication number: 20240391999
    Abstract: This invention relates to the use of KIR3DL2-targeting agents for the treatment of CTCL. The invention provides advantageous treatment regimens using anti-KIR3DL2 antibodies for the treatment of CTCL, notably in first-line CTCL.
    Type: Application
    Filed: April 29, 2024
    Publication date: November 28, 2024
    Inventors: CARINE PATUREL, HELENE SICARD
  • TREATMENT REGIMENS USING ANTI-NKG2A ANTIBODIES
    Publication number: 20240368281
    Abstract: The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.
    Type: Application
    Filed: July 15, 2024
    Publication date: November 7, 2024
    Inventors: PASCALE ANDRE, MATHIEU BLERY, CARINE PATUREL, CAROLINE SOULAS, NICOLAÏ WAGTMANN
  • CANCER TREATMENT METHODS USING ANTI-CD73 ANTIBODIES
    Publication number: 20240270865
    Abstract: The disclosure relates to methods and compositions for the treatment of cancer. Specifically, the disclosure relates to methods for administering anti-CD73 antibodies, and to methods for using anti-CD73 antibodies for the treatment of cancers, preferably HER2-positive gastric adenocarcinoma or a gastroesophageal junction adenocarcinoma in an individual.
    Type: Application
    Filed: August 6, 2021
    Publication date: August 15, 2024
    Inventors: LAURENT GAUTHIER, CARINE PATUREL, IVAN PERROT
  • Treatment regimens using anti-NKG2A antibodies
    Patent number: 12037392
    Abstract: The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.
    Type: Grant
    Filed: April 8, 2021
    Date of Patent: July 16, 2024
    Assignee: INNATE PHARMA
    Inventors: Pascale Andre, Mathieu Blery, Carine Paturel, Caroline Soulas, Nicolaï Wagtmann
  • Treatment with anti-KIR3DL2 agents
    Patent number: 11970535
    Abstract: This invention relates to the use of KIR3DL2-targeting agents for the treatment of CTCL. The invention provides advantageous treatment regimens using anti-KIR3DL2 antibodies for the treatment of CTCL, notably in first-line CTCL.
    Type: Grant
    Filed: December 8, 2020
    Date of Patent: April 30, 2024
    Assignee: INNATE PHARMA
    Inventors: Carine Paturel, Helene Sicard
  • KIR3DL2 BINDING AGENTS
    Publication number: 20240124579
    Abstract: The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.
    Type: Application
    Filed: December 27, 2023
    Publication date: April 18, 2024
    Inventors: LAURENT GAUTHIER, SIMON KOLLNBERGER, BENJAMIN ROSSI, HÉLÈNE SICARD, CARINE PATUREL, STÉPHANIE CORNEN, STÉPHANIE ZERBIB
  • CD73 blockade
    Patent number: 11958907
    Abstract: This disclosure relates to antibodies that bind an epitope present on CD73 expressed at the surface of cells, including tumor cells, and that inhibit the enzymatic (ecto-5? nucleotidase) activity of the CD73 enzyme. Such agents can be used for the treatment of diseases such as cancers.
    Type: Grant
    Filed: September 2, 2020
    Date of Patent: April 16, 2024
    Assignee: INNATE PHARMA
    Inventors: Ivan Perrot, Carine Paturel, Laurent Gauthier
  • KIR3DL2 binding agents
    Patent number: 11858990
    Abstract: The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: January 2, 2024
    Assignee: INNATE PHARMA
    Inventors: Laurent Gauthier, Simon Kollnberger, Benjamin Rossi, Hélène Sicard, Carine Paturel, Stéphanie Cornen, Stéphanie Zerbib
  • COMPOSITIONS AND METHODS FOR TREATING CANCER
    Publication number: 20230340143
    Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
    Type: Application
    Filed: February 13, 2023
    Publication date: October 26, 2023
    Inventors: Stéphanie Chanteux, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
  • SUBCUTANEOUS ANTI-C5AR ANTAGONIST TREATMENT REGIMEN WITH AVDORALIMAB
    Publication number: 20230340140
    Abstract: The present invention concerns therapeutic uses of C5aR antagonists, particularly avdoralimab, in particular in relation to chronic inflammatory or autoimmune disorders, and in particular in inflammatory skin diseases.
    Type: Application
    Filed: August 6, 2021
    Publication date: October 26, 2023
    Inventor: CARINE PATUREL
  • NEUTRALIZATION OF INHIBITORY PATHWAYS IN LYMPHOCYTES
    Publication number: 20230303691
    Abstract: This invention relates to the use of NKG2A-neutralizing agents to treat cancers that are poorly responsive to PD-1 neutralizing agents, as well as to the combined use of NKG2A-neutralizing agents and PD-1 neutralizing agents for the treatment of cancer.
    Type: Application
    Filed: June 9, 2023
    Publication date: September 28, 2023
    Inventors: PASCALE ANDRE, MATHIEU BLERY, CAROLINE DENIS, CARINE PATUREL, NICOLAI WAGTMANN
  • NEUTRALIZATION OF INHIBITORY PATHWAYS IN LYMPHOCYTES
    Publication number: 20230235060
    Abstract: The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.
    Type: Application
    Filed: February 6, 2023
    Publication date: July 27, 2023
    Inventors: PASCALE ANDRE, MATHIEU BLERY, CARINE PATUREL, NICOLAI WAGTMANN
  • RESTORATION OF T CELL ACTIVITY VIA THE CD39/CD73 AXIS
    Publication number: 20230099801
    Abstract: The present invention relates to methods of using compounds that inhibit the enzymatic activity of soluble human CD39 to treat cancer, including but not limited to the treatment of cancers characterized by CD73 expressing cells.
    Type: Application
    Filed: July 28, 2022
    Publication date: March 30, 2023
    Inventors: Stéphanie CHANTEUX, Nicolas GOURDIN, Carine PATUREL, Ivan PERROT, Benjamin ROSSI
  • Compositions and methods for treating cancer
    Patent number: 11578136
    Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: February 14, 2023
    Assignees: INNATE PHARMA, OREGA BIOTECH
    Inventors: Stéphanie Chanteux, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
  • Neutralization of inhibitory pathways in lymphocytes
    Patent number: 11572410
    Abstract: The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: February 7, 2023
    Assignee: INNATE PHARMA
    Inventors: Pascale Andre, Mathieu Blery, Carine Paturel, Nicolai Wagtmann
  • COMPOSITIONS AND METHODS FOR TREATING CANCER
    Publication number: 20230025732
    Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
    Type: Application
    Filed: June 30, 2022
    Publication date: January 26, 2023
    Inventors: Stéphanie Chanteux, Laurent Gauthier, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
  • NKp46 BINDING AGENTS
    Publication number: 20220340661
    Abstract: The present invention provides antigen-binding proteins capable of binding to NKp46 polypeptides. The antigen-binding proteins have increased activity in the treatment of disorders characterized by NKp46-expressing cells, particularly tumor cells.
    Type: Application
    Filed: June 29, 2022
    Publication date: October 27, 2022
    Inventors: NADIA ANCERIZ, MATHIEU BLERY, LAURENT GAUTHIER, CARINE PATUREL
  • Antibodies that bind human CD39 and inhibit ATPase activity of a soluble extracellular domain human CD39 polypeptide
    Patent number: 11377503
    Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: July 5, 2022
    Assignee: INNATE PHARMA
    Inventors: Stéphanie Chanteux, Laurent Gauthier, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
  • NKp46 binding agents
    Patent number: 11377492
    Abstract: The present invention provides antigen-binding proteins capable of binding to NKp46 polypeptides. The antigen-binding proteins have increased activity in the treatment of disorders characterized by NKp46-expressing cells, particularly tumor cells.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: July 5, 2022
    Assignee: INNATE PHARMA
    Inventors: Nadia Anceriz, Mathieu Blery, Laurent Gauthier, Carine Paturel
  • ANTI-CD39 ANTIBODIES
    Publication number: 20220056145
    Abstract: The present invention relates to antigen-binding compounds that inhibit CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g. cancer.
    Type: Application
    Filed: March 10, 2021
    Publication date: February 24, 2022
    Inventors: LAURENT GAUTHIER, CARINE PATUREL, IVAN PERROT